Compare RZLT & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | MTLS |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.8M | 431.6M |
| IPO Year | 2011 | 2014 |
| Metric | RZLT | MTLS |
|---|---|---|
| Price | $3.90 | $8.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 174.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.38 |
| Revenue Next Year | N/A | $6.45 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $4.78 |
| 52 Week High | $11.46 | $8.08 |
| Indicator | RZLT | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 79.94 |
| Support Level | $3.69 | $6.37 |
| Resistance Level | $5.36 | N/A |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 40.11 | 94.12 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.